Company news

aTyr Pharma, Inc. news in 2020

aTyr Pharma, Inc.'s news releases, calls and decks from 2020, newest first.

View company

aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

December 20, 2020

aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update

November 11, 2020

aTyr Pharma Announces Publication in the Journal mAbs

November 10, 2020

aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

November 9, 2020

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5: 00 pm EST / 2: 00 pm PST

November 4, 2020

aTyr Pharma Announces Research Collaboration with Medical University of South Carolina

October 28, 2020

aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

October 25, 2020

aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan

September 14, 2020

aTyr Pharma Announces $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

September 13, 2020

aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs

August 12, 2020

aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan

August 10, 2020

aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II

June 21, 2020

aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

June 14, 2020

aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19

May 11, 2020

aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine

May 4, 2020

aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application

April 20, 2020

aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update

March 25, 2020

aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform

March 23, 2020

aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th

March 18, 2020

Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific Advisor

March 16, 2020

aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering

March 9, 2020

aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology

February 26, 2020

aTyr Pharma Announces Pricing of $18 million Underwritten Public Offering

February 5, 2020

aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan

January 5, 2020

Decks in 2020